Related Experiment Video
Updated: Jul 3, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 9, 2011
Treatment of bacterial infections in children with sultamicillin
H Scholz1, X Märker, T Rockstroh
1Paediatric Institute for Infectious Diseases, Institute for Infectiology, Microbiology and Hygiene, Berlin-Buch, Wiltbergstrasse 50, D-13125 Berlin-Buch, Germany.
Abstract:
Infections caused by beta-lactamase-producing pathogens should be treated with beta-lactamase-stable antibiotics or with penicillin-derivatives in combination with inhibitors. Sulbactam, which acts as a beta-lactamase inhibitor, works in conjunction with ampicillin by extending the spectrum of ampicillin to include ampicillin-resistant germs. Sultamicillin is an active substance that combines sulbactam and ampicillin to form an ester. Sultamicillin's bio-availability remains high even after eating. For children, the dosage is 50 mg/kg/day, in two doses. The prospective study of 100 patients of between 6 months and 12 years of age with respiratory, skin, and mucous membrane infections produced a therapy success rate of 90%. The most significant side-effects were exanthemas and diarrhoea.
Insights
Sultamicillin, a combination of ampicillin and the beta-lactamase inhibitor sulbactam, effectively treats infections in children. This antibiotic demonstrated a 90% success rate in a study, with common side-effects including rash and diarrhea.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Background:
- Beta-lactamase-producing pathogens necessitate treatment with beta-lactamase-stable antibiotics or penicillin derivatives combined with inhibitors.
- Sulbactam functions as a beta-lactamase inhibitor, enhancing ampicillin's spectrum against resistant bacteria.
Purpose of the Study:
- To evaluate the efficacy and safety of sultamicillin in treating infections in pediatric patients.
- To assess the therapeutic success rate and identify common side-effects of sultamicillin treatment.
Main Methods:
- A prospective study involving 100 pediatric patients (6 months to 12 years) with respiratory, skin, and mucous membrane infections.
- Patients received a dosage of 50 mg/kg/day of sultamicillin, administered in two divided doses.
- Therapy success and adverse events were monitored throughout the study.
Main Results:
- Sultamicillin achieved a high therapy success rate of 90% in the studied pediatric population.
- The most frequently observed side-effects were exanthemas (rashes) and diarrhea.
- Sultamicillin exhibits favorable bioavailability, even when administered after meals.
Conclusions:
- Sultamicillin is an effective treatment option for pediatric infections caused by susceptible pathogens.
- The drug is generally well-tolerated, with manageable side-effects.
- Sultamicillin offers a convenient dosing regimen and good bioavailability in children.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Pyelonephritis II: Diagnostic Studies and Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Tonsillitis II: Management
Mechanism of Antibiotic Resistance in MRSA